公开(公告)号：US20150157588A1

公开(公告)日：2015-06-11

申请号：US14412838

申请日：2013-07-04

Applicant: Yeda Research and Development Co., Ltd.

Inventor： Irun R. Cohen ,  Meir Shinitzky ,  Raanan Margalit ,  Michal Cohen-Sfady ,  Alexandra Zanin-Zhorov

IPC: A61K31/216

CPC classification number: A61K31/216

Abstract: The present invention relates to the compound amino-phenyl-acetic acid octadec-(Z)-9-enyl ester, an enantiomer thereof or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising it, for use in the treatment of tumors and metastases, and to methods for treating a tumor or metastases comprising administering said compound to a subject in need thereof. The present invention particularly relates to said compound when it is dissolved in an ethanol solution.

Abstract translation: 本发明涉及用于治疗肿瘤和转移的化合物氨基 - 苯基 - 乙酸十八 - （Z）-9-烯酯，其对映异构体或其药学上可接受的盐或包含它的药物组合物， 以及用于治疗肿瘤或转移的方法，包括向有需要的受试者施用所述化合物。 当本发明溶于乙醇溶液时，本发明特别涉及所述化合物。

公开(公告)号：US20150057219A1

公开(公告)日：2015-02-26

申请号：US14468672

申请日：2014-08-26

Applicant: Yeda Research and Development Co., Ltd.

Inventor： Yoram SHECHTER ,  Matityahu Fridkin ,  Haim Tsubery

IPC: A61K47/48 ,  A61K38/22

CPC classification number: A61K47/60 ,  A61K31/7036 ,  A61K38/1709 ,  A61K38/212 ,  A61K38/22 ,  A61K38/2242 ,  A61K38/2278 ,  A61K38/26 ,  A61K38/27 ,  A61K38/28 ,  A61K47/54 ,  A61K47/545 ,  C07D207/404 ,  C07D207/416 ,  C07D207/452 ,  C07D403/12

Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.

Abstract translation: 可逆的聚乙二醇化药物通过衍生自选自氨基，羟基，巯基，磷酸酯和/或羧基的药物的游离官能团与对温和碱性条件敏感的基团如9-芴基甲氧基羰基（Fmoc）或2-磺基-9-芴基甲氧基羰基 （FMS），连接有PEG部分的基团。 在这些聚乙二醇化药物中，PEG部分和药物残留物不直接相互连接，而是两个残基都连接到对碱基高度敏感并在生理条件下可去除的支架Fmoc或FMS结构的不同位置。 药物优选是含有氨基的药物，最优选低分子量或中等分子量的肽和蛋白质。 提供了类似的分子，其中蛋白质载体或另一种聚合物载体取代了PEG部分。

公开(公告)号：US20150049542A1

公开(公告)日：2015-02-19

申请号：US14385006

申请日：2013-03-13

Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD. ,  YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.

Inventor： Ron Naaman ,  Yossef Paltiel ,  Sivan Kober ,  Gilad Gotesman

IPC: G11C11/16 ,  H03K19/00

CPC classification number: G11C11/16 ,  B82Y10/00 ,  G11C11/161 ,  G11C11/5607 ,  G11C13/0014 ,  G11C13/0016 ,  G11C13/0019 ,  H01L27/285 ,  H01L29/0665 ,  H01L43/10 ,  H01L51/0093 ,  H01L51/0595 ,  H03K19/0008

Abstract: In accordance with one exemplary embodiment of the present technique, there is disclosed a spins selective device, including a first layer comprising a ferromagnetic material. The spin selective device further includes a second layer coupled to the first layer. The second layer includes at least one molecule having a specified chirality, such that when an electrical current flows between the first layer and the second layer one or more regions of the ferromagnetic material become magnetically polarized along a certain direction.

Abstract translation: 根据本技术的一个示例性实施例，公开了一种自旋选择装置，包括包含铁磁材料的第一层。 自旋选择装置还包括耦合到第一层的第二层。 第二层包括具有指定手性的至少一个分子，使得当电流在第一层和第二层之间流动时，铁磁材料的一个或多个区域沿着某一方向变得磁极化。

公开(公告)号：US20150047985A1

公开(公告)日：2015-02-19

申请号：US14372064

申请日：2013-01-13

Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.

Inventor： Jacob Karni ,  Yury Alioshin ,  David Banitt ,  David Scheiner ,  Roi Harpaz ,  Baruch Finarov

IPC: C25B1/00 ,  C25B9/08 ,  C25B1/10 ,  C25B9/18

CPC classification number: C25B1/003 ,  C25B1/00 ,  C25B1/04 ,  C25B1/10 ,  C25B9/00 ,  C25B9/08 ,  C25B9/18 ,  C25B15/00 ,  F24S20/20 ,  Y02E60/366 ,  Y02E70/10 ,  Y02P20/134

Abstract: A solar-driven apparatus is provided having: a cavity having at least one optical window for collecting electromagnetic radiation associated with solar energy impinging on said at least one optical window; a reaction assembly located inside the cavity and adapted to enable carrying out electrolysis process of at least one raw fluid utilizing energy derived partially from the solar radiation and partially from an electric source; one or more ingress units operative to allow introduction of the raw fluid into the apparatus; and one or more egress units operative to allow exit of the electrolysis process' products from the solar driven apparatus.

Abstract translation: 提供了一种太阳能驱动装置，其具有：具有至少一个光学窗口的空腔，用于收集与所述至少一个光学窗口上的太阳能相关联的电磁辐射; 反应组件，其位于所述空腔内并且适于使得能够利用部分地从所述太阳辐射部分地衍生的部分地从电源产生的能量进行至少一种原始流体的电解过程; 一个或多个入口单元可操作以允许将原始流体引入到设备中; 并且一个或多个出口单元可操作以允许从太​​阳能驱动设备排出电解过程的产品。

公开(公告)号：US20140369974A1

公开(公告)日：2014-12-18

申请号：US14367923

申请日：2012-12-20

Applicant: Yeda Research and Development Co., Ltd.

Inventor： Yair Reisner ,  Esther Bachar-Lustig

IPC: A61K35/28 ,  A61K31/675

CPC classification number: A61K35/28 ,  A61K31/198 ,  A61K31/255 ,  A61K31/661 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/22 ,  A61K35/34 ,  A61K35/36 ,  A61K35/38 ,  A61K35/39 ,  A61K35/407 ,  A61K35/42 ,  A61K39/3955 ,  A61K2035/124 ,  A61K2039/507 ,  A61K2039/515 ,  C12N5/0087 ,  A61K2300/00

Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The methos comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoetic cells, wherein the T cell depleted immature hematopoetic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject, and wherein the T cell depleted immature hematopoetic cells are obtained by separating the T cells from the immature hematopoetic cells by magnetic cell sorting, and (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per body weight, thereby treating the subject.

Abstract translation: 公开了一种治疗需要非同基因细胞或组织移植物的受试者的方法。 该方法包括：（a）将一定剂量的T细胞耗尽的未成熟造血细胞移植到受试者中，其中所述T细胞耗尽的未成熟造血细胞每个体重为每公斤体重小于5×10 5个CD3 + T细胞，其中所述剂量 包括至少约5×106个CD34 +细胞/千克体重的受试者，并且其中所述T细胞耗尽的未成熟造血细胞是通过磁细胞分选从未成熟的造血细胞分离T细胞获得的，和（b） 患有治疗有效量的环磷酰胺，其中治疗有效量包含25-200mg /体重，从而治疗受试者。

公开(公告)号：US08889865B2

公开(公告)日：2014-11-18

申请号：US14297116

申请日：2014-06-05

Applicant: Yeda Research and Development Co. Ltd.

Inventor： David Milstein ,  Chidambaram Gunanathan

IPC: C07F15/00 ,  B01J21/02 ,  C07F5/02 ,  C07C209/16 ,  C07D307/52 ,  B01J31/14 ,  C07D213/38 ,  C07D305/06

CPC classification number: C07C209/16 ,  B01J31/146 ,  C07B43/04 ,  C07C213/02 ,  C07C2601/14 ,  C07D213/38 ,  C07D305/06 ,  C07D307/52 ,  C07F9/60 ,  C07F9/64 ,  C07F15/0046 ,  C07C211/07 ,  C07C211/17 ,  C07C211/27 ,  C07C217/08 ,  C07C217/58

Abstract: The present invention provides novel ruthenium based catalysts, and a process for preparing amines, by reacting a primary alcohol and ammonia in the presence of such catalysts, to generate the amine and water. According to the process of the invention, primary alcohols react directly with ammonia to produce primary amines and water in high yields and high turnover numbers. This reaction is catalyzed by novel ruthenium complexes, which are preferably composed of quinolinyl or acridinyl based pincer ligands.

Abstract translation: 本发明提供新型的钌基催化剂，以及通过在这种催化剂存在下使伯醇和氨反应制备胺的方法，以产生胺和水。 根据本发明的方法，伯醇直接与氨反应，以高产率和高的周转数产生伯胺和水。 该反应由新的钌络合物催化，其优选由喹啉基或吖啶基的钳形配体组成。

公开(公告)号：US20140336105A1

公开(公告)日：2014-11-13

申请号：US14323408

申请日：2014-07-03

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Yechiel Shai ,  Avner Fink ,  Shay Yaari ,  Tova Waks ,  Zelig Eshhar ,  Christopher J. Arnush

IPC: C07K7/08 ,  C07K14/00

CPC classification number: C07K7/08 ,  A61K38/08 ,  C07K7/00 ,  C07K14/001

Abstract: Anti-inflammatory peptides and pharmaceutical compositions including lysine, alanine, leucine and/or valine for treating inflammatory conditions and uses thereof. Anti-inflammatory peptides for treating IgE-mediated allergies and inflammatory conditions caused by a microbial infection including but not limited to sepsis.

Abstract translation: 抗炎肽和药物组合物，包括用于治疗炎性病症的赖氨酸，丙氨酸，亮氨酸和/或缬氨酸及其用途。 用于治疗由微生物感染引起的IgE介导的过敏和炎性病症的抗炎肽，包括但不限于败血症。

公开(公告)号：US20140315740A1

公开(公告)日：2014-10-23

申请号：US14320530

申请日：2014-06-30

Applicant: Yeda Research And Development Co. Ltd.

Inventor： Irun R. Cohen ,  Francisco Javier Quintana ,  Eytan Domany ,  Gad Elizur ,  Peter H. Hagedorn

IPC: G01N33/564

CPC classification number: G01N33/564

Abstract: A method of diagnosing an immune disease, or a predisposition thereto, in a subject is disclosed. The method comprises determining a capacity of immunoglobulins of the subject to specifically bind each antigen probe of an antigen probe set, wherein the antigen probe set comprises a plurality of antigen probes selected from the group consisting of at least a portion of a cell/tissue structure molecule, at least a portion of a heat shock protein, at least a portion of an immune system molecule, at least a portion of a homopolymeric polypeptide, at least a portion of a hormone, at least a portion of a metabolic enzyme, at least a portion of a microbial antigen, at least a portion of a molluscan antigen, at least a portion of a nucleic acid, at least a portion of a plant antigen, at least a portion of plasma molecule, and at least a portion of a tissue antigen, wherein the capacity is indicative of the immune disease or the predisposition thereto, thereby diagnosing the immune disease, or the predisposition thereto, in the subject.

Abstract translation: 公开了一种在受试者中诊断免疫疾病或其倾向的方法。 该方法包括确定受试者的免疫球蛋白的能力以特异性结合抗原探针组的每个抗原探针，其中所述抗原探针组包含多个选自下组的抗原探针：至少一部分细胞/组织结构 分子，至少一部分热休克蛋白，至少一部分免疫系统分子，至少一部分均聚多肽，至少一部分激素，代谢酶的至少一部分，至少 一部分微生物抗原，至少一部分软体动物素抗原，至少一部分核酸，至少一部分植物抗原，至少一部分血浆分子和至少一部分组织 抗原，其中所述能力指示免疫疾病或其易感性，从而诊断受试者的免疫疾病或其易感性。

公开(公告)号：US08859772B2

公开(公告)日：2014-10-14

申请号：US13771498

申请日：2013-02-20

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Boris Rybtchinski ,  Paramasivan Rajasingh ,  Elijah Shirman

IPC: C07F7/02 ,  C07D471/08

CPC classification number: C07D471/06

Abstract: The present invention is directed to novel process for the preparation of regioselective perylenediimides derivatives, specifically mono and dibrominated derivatives.

Abstract translation: 本发明涉及用于制备区域选择性苝酰亚胺衍生物，特别是单溴代衍生物和二溴衍生物的新方法。

公开(公告)号：US20140178899A1

公开(公告)日：2014-06-26

申请号：US14105148

申请日：2013-12-12

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Adi Kimchi ,  Einat Zalckvar

IPC: G01N33/53

CPC classification number: G01N33/53 ,  C07K14/4703 ,  C07K14/4747 ,  C07K14/82 ,  C07K16/28 ,  C07K16/44 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/156 ,  G01N33/566 ,  G01N33/574 ,  G01N33/6893

Abstract: The present invention relates to antibodies specific for human Beclin-1 protein phosphorylated at position Thr 119 and uses thereof. In particular, these antibodies are useful in diagnosing diseases associated with impaired autophagy including cancer and neurodegenerative diseases. The invention further relates to human Beclin-1 mutated at position 119 with a phospho-mimicking residue and uses thereof for treating cancer and neurodegenerative diseases.

Abstract translation: 本发明涉及在Thr119位点磷酸化的人Beclin-1蛋白的特异性抗体及其应用。 特别地，这些抗体可用于诊断与自身受损有关的疾病，包括癌症和神经变性疾病。 本发明还涉及在位置119突变的人类Beclin-1，其具有磷酸模拟残基及其用于治疗癌症和神经变性疾病的用途。